Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Cancer Risks in BRCA2 Mutation Carriers

Cancer Risks in BRCA2 Mutation Carriers AbstractBACKGROUND: Carriers of germline mutations in the BRCA2 gene are known to be at highrisk of breast and ovarian cancers, but the risks of other cancers in mutation carriers areuncertain. We investigated these risks in 173 breast-ovarian cancer families with BRCA2mutations identified at 20 centers in Europe and North America. METHODS: Other canceroccurrence was determined in a final cohort of 3728 individuals, among whom 681 persons hadbreast or ovarian cancer and 3047 persons either were known mutation carriers, were first-degreerelatives of known mutation carriers, or were first-degree relatives of breast or ovarian cancerpatients. Incidence rates were compared with population-specific incidence rates, and relativerisks (RRs) to carriers, together with 95% confidence intervals (CIs), were estimated byuse of a maximum likelihood approach. Three hundred thirty-three other cancers occurred in thiscohort. RESULTS: Statistically significant increases in risks were observed for prostate cancer(estimated RR = 4.65; 95% CI = 3.48-6.22), pancreatic cancer (RR=3.51; 95% CI = 1.87-6.58), gallbladder and bile duct cancer (RR=4.97; 95% CI = 1.50-16.52), stomach cancer (RR = 2.59;95%CI = 1.46-4.61), and malignant melanoma (RR = 2.58; 95% CI=1.28-5.17). The RR for prostate cancer for men below the age of 65 years was 7.33(95% CI = 4.66-11.52). Among women who had already developed breast cancer,the cumulative risks of a second, contralateral breast cancer and of ovarian cancer by the age of70 years were estimated to be 52.3% (95% CI =41.7%-61.0%) and 15.9% (95% CI =8.8%-22.5%), respectively. CONCLUSIONS: In addition to the large risks of breastand ovarian cancers, BRCA2 mutations may be associated with increased risks of several othercancers. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of the National Cancer Institute Oxford University Press

Cancer Risks in BRCA2 Mutation Carriers

Journal of the National Cancer Institute , Volume 91 (15) – Aug 4, 1999

Loading next page...
 
/lp/oxford-university-press/cancer-risks-in-brca2-mutation-carriers-fPGAE9gn1X

References (18)

Publisher
Oxford University Press
Copyright
Oxford University Press
ISSN
0027-8874
eISSN
1460-2105
DOI
10.1093/jnci/91.15.1310
Publisher site
See Article on Publisher Site

Abstract

AbstractBACKGROUND: Carriers of germline mutations in the BRCA2 gene are known to be at highrisk of breast and ovarian cancers, but the risks of other cancers in mutation carriers areuncertain. We investigated these risks in 173 breast-ovarian cancer families with BRCA2mutations identified at 20 centers in Europe and North America. METHODS: Other canceroccurrence was determined in a final cohort of 3728 individuals, among whom 681 persons hadbreast or ovarian cancer and 3047 persons either were known mutation carriers, were first-degreerelatives of known mutation carriers, or were first-degree relatives of breast or ovarian cancerpatients. Incidence rates were compared with population-specific incidence rates, and relativerisks (RRs) to carriers, together with 95% confidence intervals (CIs), were estimated byuse of a maximum likelihood approach. Three hundred thirty-three other cancers occurred in thiscohort. RESULTS: Statistically significant increases in risks were observed for prostate cancer(estimated RR = 4.65; 95% CI = 3.48-6.22), pancreatic cancer (RR=3.51; 95% CI = 1.87-6.58), gallbladder and bile duct cancer (RR=4.97; 95% CI = 1.50-16.52), stomach cancer (RR = 2.59;95%CI = 1.46-4.61), and malignant melanoma (RR = 2.58; 95% CI=1.28-5.17). The RR for prostate cancer for men below the age of 65 years was 7.33(95% CI = 4.66-11.52). Among women who had already developed breast cancer,the cumulative risks of a second, contralateral breast cancer and of ovarian cancer by the age of70 years were estimated to be 52.3% (95% CI =41.7%-61.0%) and 15.9% (95% CI =8.8%-22.5%), respectively. CONCLUSIONS: In addition to the large risks of breastand ovarian cancers, BRCA2 mutations may be associated with increased risks of several othercancers.

Journal

Journal of the National Cancer InstituteOxford University Press

Published: Aug 4, 1999

There are no references for this article.